Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1704-1711

  Bae, Jung Woo ^a   Jang, Choon Gon ^a   Lee, Seok Young ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

clopidogrel; CYP2B6; CYP2C19; drug interaction; Sibutramine

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DIDESMETHYL SIBUTRAMINE; MONODESMETHYL SIBUTRAMINE; SIBUTRAMINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; NORMAL HUMAN;

ADULT; APPETITE DEPRESSANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD PRESSURE; CYCLOBUTANES; DRUG INTERACTIONS; FEMALE; GENOTYPE; HALF-LIFE; HEART RATE; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PLATELET AGGREGATION INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 82955201630     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010388651     Document Type: Article

References (33)

1. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988 ; 12: 575-584
2. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 1989 ; 28: 129-134 (Pubitemid 19056220)
3. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998 ; 56: 1093-1124 (Pubitemid 29010230)
4. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol. 2002 ; 440: 119-128 (Pubitemid 34458019)
5. Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP. Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol. 2000 ; 397: 93-102 (Pubitemid 30323815)
6. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008 ; 9: 378-387 (Pubitemid 351842191)
7. Deitel M. Sibutramine warning: hypertension and cardiac arrhythmias reported. Obes Surg. 2002 ; 12: 422 (Pubitemid 34621046)
8. Harrison-Woolrych M, Clark DW, Hill GR, et al. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol. 2006 ; 61: 464-469
9. Ernest D, Gershenzon A, Corallo CE, Nagappan R. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother. 2008 ; 42: 1514-1517
10. Follow-up to the November 2009 Early communication about an ongoing safety review of sibutramine, marketed as Meridia. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm. Accessed August 1, 2010.
11. Meridia (sibutramine hydrochloride): Follow-up to an early communication about an ongoing safety review. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm. Accessed August 1, 2010.
12. Questions and answers on the suspension of medicines containing sibutramine. http://www.ema.europa.eu/pdfs/human/referral/sibutramine/ Sibutramine-Q&A-80817909en.pdf. Accessed August 1, 2010.
13. Meridia (sibutramine) label information. Abbott Park, Illinois: Abbott Laboratories. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020632s032lbl.pdf.
14. Kaiser PE, Hinson JL. Sibutramine: dose response and plasma metabolite concentrations in weight loss. J Clin Pharmacol. 1994 ; 34: 1019
15. Richter T, Mürdter TE, Heinkele G, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther. 2004 ; 308: 189-197 (Pubitemid 38090717)
16. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008 ; 23: 412-420
17. Nishiya Y, Hagihara K, Ito T, et al. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos. 2009 ; 37: 589-593
18. Nishiya Y, Hagihara K, Kurihara A, et al. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica. 2009 ; 39: 836-843
19. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005 ; 77: 553-559 (Pubitemid 40824968)
20. Chen BL, Chen Y, Tu JH, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol. 2009 ; 49: 574-581
21. Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos. 2008 ; 36: 1679-1688
22. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 ; 46: 594-598 (Pubitemid 24334747)
23. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 ; 269: 15419-15422
24. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 ; 79: 103-113 (Pubitemid 43069582)
25. Nakajima M, Komagata S, Fujiki Y, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007 ; 17: 431-445 (Pubitemid 46763388)
26. Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001 ; 29: 1480-1484 (Pubitemid 33000696)
27. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 ; 33: 262-270 (Pubitemid 40216594)
28. Ramírez J, Innocenti F, Schuetz EG, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 ; 32: 930-936 (Pubitemid 39096052)
29. Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther. 2009 ; 86: 511-518
30. Chung JY, Jang SB, Lee YJ, Park MS, Park K. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol. :
31. Link M, Hakala KS, Wsól V, Kostiainen R, Ketola RA. Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study. J Mass Spectrom. 2006 ; 41: 1171-1178 (Pubitemid 44454170)
32. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000 ; 1: 127-139
33. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 ; 29: 509-516 (Pubitemid 40592993)